SCHEMBL14920239

SCHEMBL14920239

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1nc2ccc(Br)cc2n1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.41
USP30 Q70CQ3 2/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
GSK3B P49841 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
NR1H2 P55055 8/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
AAK1 Q2M2I8 1/20 0.34
SOS1 Q07889 1/20 0.34
NR1H3 Q13133 3/20 0.34
PIK3R1 P27986 1/20 0.33
PIK3CA P42336 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6120980 0.96 BACE1 (0.40) BACE1USP30CCNB2CDK1CCNB1
SCHEMBL481590 0.91 BACE1 (0.41) BACE1USP30CCNB2CDK1CCNB1
SCHEMBL482136 0.88 BACE1 (0.40) BACE1USP30CCNB2CDK1CCNB1
SCHEMBL27851953 0.86 L3MBTL1 (0.35) BACE1USP30AAK1SOS1MEN1
SCHEMBL30781510 0.86 NR1H2 (0.39) NR1H2GABRG2GABRB3GABRA5NR1H3
SCHEMBL2779797 0.86 NR1H2 (0.39) NR1H2GABRG2GABRB3GABRA5NR1H3
SCHEMBL10299255 0.83 L3MBTL1 (0.45) NR1H2NR1H3ALDH1A1MAPTKMT2A
SCHEMBL18459405 0.82 BRD4 (0.42) MEN1NPC1ALDH1A1MAPTRAB9A
SCHEMBL30847402 0.81 USP30 (0.39) BACE1USP30CCNB2CDK1CCNB1
SCHEMBL12158 0.81 USP30 (0.39) BACE1USP30CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2773641-B1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2017-09-27 EP disclosed
US-9481677-B2 Biaryl ether sulfonamides and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2016-11-01 US disclosed
US-9365578-B2 2016-06-14 US disclosed
US-20140256736-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2014-09-11 US disclosed
EP-2773641-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS Xenon Pharmaceuticals Inc. (CA) 2014-09-10 EP disclosed
WO-2013064984-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256736-A1 BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS TRPV1, TRPV3, TRPV2 BACE1 2265/4885USP30 2833/4885CCNB2 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.